- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.10. | Liminatus Pharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 25.08. | Liminatus Pharma, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.08. | Liminatus Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.07. | Liminatus plans to invest up to $500 million in BNB coin | 6 | Investing.com | ||
| 28.07. | Liminatus Pharma Inc. to Launch "American BNB Strategy" Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative | 12 | GlobeNewswire (USA) | ||
| 25.07. | Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies | 292 | GlobeNewswire (Europe) | LA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies... ► Artikel lesen | |
| LIMINATUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 24.07. | Liminatus Pharma stock soars after engaging Digital Offering for capital raise | 3 | Investing.com | ||
| 24.07. | Pre-market Movers: Sadot Group, Community Health Systems, Liminatus Pharma, MaxLinear, Incannex Healthcare | 749 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.10 A.M. ET).In the Green Liminatus Pharma, Inc. (LIMN) is up over 25% at... ► Artikel lesen | |
| 24.07. | Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy | 2 | GlobeNewswire (USA) | ||
| 22.07. | Liminatus gains amid review to consider digital assets for treasury management | 2 | Seeking Alpha | ||
| 22.07. | Liminatus Pharma explores digital assets for treasury management | 1 | Investing.com | ||
| 22.07. | Liminatus Pharma Inc.: Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy | 183 | GlobeNewswire (Europe) | LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies... ► Artikel lesen | |
| 11.07. | Liminatus Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.07. | Liminatus Pharma bildet Konsortium für Bauchspeicheldrüsenkrebs-Diagnosekit | 2 | Investing.com Deutsch | ||
| 03.07. | Liminatus Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.06. | Liminatus Pharma files to sell 6.9M shares of common stock | 2 | Seeking Alpha | ||
| 24.06. | Liminatus Pharma, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 24.06. | Liminatus Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.06. | Pre-market Movers: Creative Global Technology, Liminatus Pharma, CureVac, Jupiter Neurosciences, Tonix Pharmaceuticals | 824 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.05 A.M. ET).In the Green Creative Global Technology Holdings Limited (CGTL)... ► Artikel lesen | |
| 05.06. | Liminatus Pharma stock gains on regaining compliance with Nasdaq | 1 | Seeking Alpha |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,065 | -0,10 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 5,500 | -3,51 % | Sana Biotech surges as Eric Jackson calls it a 100-bagger | ||
| ARCTURUS THERAPEUTICS | 11,600 | 0,00 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| RANI THERAPEUTICS | 2,415 | 0,00 % | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,745 | -5,97 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| BICARA THERAPEUTICS | 16,450 | -3,35 % | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC | BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients... ► Artikel lesen | |
| EVOTEC | 6,726 | -1,41 % | Übernahme von Vidac Pharma und Evotec? 400 Mrd. USD bei Pfizer, Merck und Co im Feuer! | Alarm bei Big Pharma! Donald Trump scheint bei der Reduzierung von Medikamentenpreisen ernst zu machen. Gleichzeitig laufen Patente bei Blockbustern aus und ein 400 Mrd. USD Umsatzausfall droht. Pfizer... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,140 | 0,00 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| NURIX THERAPEUTICS | 10,640 | +2,01 % | Nurix Therapeutics, Inc.: Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia | 600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated... ► Artikel lesen | |
| LENZ THERAPEUTICS | 32,690 | -2,45 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen | |
| BIONTECH | 91,50 | -0,81 % | Übernahmefieber und KI-Chance: BioNTech, Novo Nordisk, PanGenomic Health Aktie | Übernahmefieber im Pharma- und Biotech-Bereich. Novo Nordisk hat nach der angekündigten Milliardenübernahme in den USA den nächsten Deal gemeldet. Die Dänen sehen ein mögliches Best-in-Class-Therapeutikum... ► Artikel lesen | |
| COGENT BIOSCIENCES | 14,830 | -6,49 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib | Detailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this... ► Artikel lesen | |
| DISC MEDICINE | 87,20 | +1,22 % | Disc Medicine Inc: Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner's National... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,670 | -7,43 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 10,520 | -6,41 % | 4D Molecular Therapeutics stock maintains Outperform rating at RBC Capital |
LIMINATUS PHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -3,33 % bei einem Aktienkurs von 1,160 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIMINATUS PHARMA INC finden Sie auf Wallstreet Online.